Addendum
Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93
Report documents
-
Addendum
Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93
Dossier assessment
Type 2 diabetes mellitus in adults
Result of dossier assessment unchanged after addendum:
Monotherapy in adults in whom diet and exercise alone do not provide adequate glycaemic control and the use of metformin is considered inappropriate due to intolerance or contraindications: added benefit not proven.
Combination therapy in adults in whom diet and exercise and treatment with 1 other blood-glucose lowering drug (except insulin) do not provide adequate glycaemic control: added benefit not proven.
Combination therapy in adults in whom diet and exercise and treatment with at least 2 other blood-glucose lowering drugs (except insulin) do not provide adequate glycaemic control: added benefit not proven.
Combination therapy in adults in whom diet and exercise and treatment with insulin (with or without 1 other blood-glucose lowering drug) do not provide adequate glycaemic control: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021.04.15 A G-BA decision was published.
Project details
- Project no.
- A21-30
- Commission
- Commission awarded on 10.03.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed